Theranos, the single-blooddrop lab testing company is hitting rock bottom.

It's a shame that they are failing, but they messed up so badly that they didn't leave any space for a revival of the project.
This whole cherade has started a backlash of skepticism toward start-ups that are worth more than a billion dollars in estimation. (Theranos was worth 9 billion)
There's also criticism over the fact that Theranos used mass-media hype and stealth research as public relation strategy, instead of sumbitting their research to peer-review journals as most innovators do.